venclexta 100 mg 120 tablets

Venclxta Tablets are a targeted therapy used to treat certain types of blood cancer. They contain venetoclax as the active ingredient, which works by inhibiting the B-cell lymphoma 2 (BCL-2) protein that helps cancer cells survive.

By blocking this protein, the medication promotes the natural death of malignant cells and helps slow the progression of the disease.

Venclxta is used under the supervision of a specialist for the treatment of patients with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). When used according to the prescribed treatment regimen, it provides advanced therapeutic benefits and improves treatment outcomes.

Venclxta Ingredients

Venetoclax.

Venclxta Strengths

100 mg tablets, pack containing 120 tablets.

Starter pack containing 10 mg, 50 mg, and 100 mg tablets (42 tablets).

Uses of Venclxta

• Treatment of chronic lymphocytic leukemia (CLL) in adults.

• Treatment of acute myeloid leukemia (AML) in combination with other anticancer medications.

• Inhibition of the BCL-2 protein that protects cancer cells from programmed cell death.

• Promotion of apoptosis (programmed cell death) in malignant cells.

• Reduction of disease relapse and improvement of treatment response.

Venclxta Dosage

Treatment begins with a 5-week dose-escalation schedule to reduce the risk of tumor lysis syndrome (TLS). The usual starting dose is 20 mg once daily, gradually increased to 50 mg, 100 mg, 200 mg, and finally 400 mg once daily.

The tablets should be taken with food and an adequate amount of water at the same time each day. Patients should strictly follow the dose-escalation schedule prescribed by their physician.

Side Effects of Venclxta

• Decreased white blood cell and platelet counts.

• Fatigue and persistent tiredness.

• Nausea, vomiting, diarrhea, or constipation.

• Anemia and reduced red blood cell counts.

• Increased susceptibility to bacterial and viral infections.

• Risk of tumor lysis syndrome due to the rapid destruction of cancer cells.

Contraindications of Venclxta

Venclxta should not be used in patients with severe hypersensitivity to venetoclax or any of the product's ingredients. Concomitant use with strong CYP3A inhibitors is contraindicated during treatment initiation and the dose-escalation phase because it may significantly increase venetoclax exposure and the risk of serious toxicity.

The medication should also be avoided during pregnancy and breastfeeding due to potential risks to the fetus or infant. Patients with severe, uncontrolled liver or kidney impairment should use the medication only after careful medical evaluation.

Venclxta Alternatives

• Venetoclax.

• Imbruvica.

Use During Pregnancy and Breastfeeding

Venclxta should not be used during pregnancy because it may cause serious harm to the developing fetus. A pregnancy test should be performed before starting treatment to confirm that the patient is not pregnant.

Women of childbearing potential should use an effective method of contraception during treatment and for the period recommended by their physician after the final dose. Breastfeeding should also be discontinued throughout the course of treatment.

Storage Conditions

• Store in a dry place at a temperature below 30°C.

• Keep the tablets in their original container to protect them from moisture and light.

• Do not transfer the tablets to another container.

• Keep out of the reach and sight of children.